News
ERAS
16.80
+8.53%
1.32
Erasca Stock In Focus As Cancer Drug Combination Trial Begins
Simply Wall St · 5h ago
Erasca Inc options imply 12.8% move in share price post-earnings
TipRanks · 20h ago
Erasca's Cash Runway Could End Before Its Pan-RAS Bet Pays Off
Barchart · 1d ago
Weekly Report: what happened at ERAS last week (1102-1106)?
Weekly Report · 3d ago
Erasca (ERAS) Could Be 45% Undervalued On New Cancer Trial Progress
Simply Wall St · 6d ago
What Erasca (ERAS)'s Cancer Drug Trial Start Means For Shareholders
Simply Wall St · 11/05 09:31
Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung Cancers
NASDAQ · 11/05 06:31
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/04 21:05
Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study
TipRanks · 11/04 14:18
Weekly Report: what happened at ERAS last week (1026-1030)?
Weekly Report · 11/02 10:10
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
Seeking Alpha · 10/30 11:08
Erasca (ERAS) Faces Legal Scrutiny, Is It Still 37% Below Fair Value?
Simply Wall St · 10/29 03:36
What Erasca Stock's Disclosure Probe Means For Shareholders
Simply Wall St · 10/27 21:14
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Erasca (ERAS) and Incyte (INCY)
TipRanks · 10/26 10:40
Weekly Report: what happened at ERAS last week (1019-1023)?
Weekly Report · 10/26 10:09
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
Barchart · 10/23 15:09
Erasca (ERAS), What Is Drawing Fresh Attention Now?
Simply Wall St · 10/20 13:45
Bank of America Securities Keeps Their Hold Rating on Erasca (ERAS)
TipRanks · 10/19 16:45
Leadership Change Could Reset The Case For Erasca (ERAS) Stock
Simply Wall St · 10/19 11:32
Weekly Report: what happened at ERAS last week (1012-1016)?
Weekly Report · 10/19 10:09
More
Webull provides a variety of real-time ERAS stock news. You can receive the latest news about Erasca, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.